Cronos Group Inc.
CRONHealthcareNASDAQDrug Manufacturers - Specialty & Generic · Last scanned Oct 24, 2026
Scan Results
Daily timeframeCronos Group Inc., a cannabinoid company, engages in the cultivation, production, distribution, and marketing of cannabis products in Canada, Israel, and internationally. Valued at $1.23B, CRON is a small-cap name in its sector. It offers dried flowers, pre-rolls, oils, vaporizers, edibles, and tinctures under the Spinach, Lord Jones, Lit, and Peace Naturals brand names.
Market Cap
$1.23B
Beta
1.20
P/E (TTM)
18.61
P/E (Fwd)
-83.75
EPS (TTM)
$0.18
EPS (Fwd)
$-0.04
ROE
7.0%
ROA
-0.1%
Cash
$797.0M
Total Debt
$1.3M
Free CF
$6.1M
52W Change
32.9%
Annual Financials
Cash vs Debt
Where CRON stands vs its 150-day and 200-day moving averages
As of the October 19, 2026 close, CRON finished 11.46% above its 150-day moving average ($2.88) and 13.83% above its 200-day moving average ($2.82). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is CRON overbought or oversold?
At the October 19, 2026 close, CRON's RSI(14) was 28.7, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $797.0M in cash comfortably exceeding the $1.3M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Annual free cash flow of $6.1M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. ROE of 7.0% points to modest capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $86.7M (2022) to $146.6M (2025), reflecting a 69% increase over the period.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing CRON.